Pictured: a collage of genetic indicators surrounding a patient with Huntingtons disease/ Nicole Bean for BioSpace
Its 100 percent fatal, hits patients in the prime of their lives, then gets passed down to 50 percent of the next generation. Thirty years after the discovery of the huntingtin gene, the biopharma industry is still searching for an effective treatment for Huntingtons disease.
Within the past few years, Roche and Wave Life Sciences have experienced high-profile failures in the space, and in late 2022, Triplet Therapeutics, a young startup with an approach targeting Huntingtons and other genetic diseases, closed its doors, and precision genetics medicine biotech NeuBase Therapeutics halted development of its Huntingtons program.
Symptomatic treatments exist for Huntingtons disease, which is caused by a CAG repeat in the first exon of the huntingtin (HTT) gene, but to date, no disease-modifying drug has made it across the finish line.
Rudolph Rudy Tanzi was part of the team that identified the Huntingtons gene chromosome in 1983. At the dawn of the genomic revolution, it was the first gene to be mapped to a human chromosome without any prior indication of the genes location. You had no idea what chromosome it was on, you had no idea what the protein defect was, Tanzi, now a professor of neurology at Harvard Medical School and Massachusetts General Hospital, told BioSpace. The search, which Tanzi compared to looking for 12 pieces of hay in 23 haystacks, took two years.
Instrumental to the discovery was a large group of patients in Venezuela. Huntingtons disease was evident in more than 12 families in this country, each with 10 or 11 children, Tanzi said. Once we had [those families], we tested that same DNA marker from chromosome 4, and that sealed it . . . . It was clear wed found the gene.
Ten years later, the pathogenic mutation in the huntingtin gene was identified as a CAG-repeat expansion. This mutation causes brain cells to die, leading to a host of progressive cognitive, psychiatric and movement disorders.
Theres been a lot of progress on mechanism, said Michael Hayden, CEO and founder of Prilenia Therapeutics, who was also involved in early linkage studies. Prilenia is developing treatments for Huntingtons and other neurodegenerative diseases. But . . . from the time you define mechanism to the time you have a drug can take twenty years.
Thirty years on, the search for a disease-modifying drug for Huntingtons continues.
After discovering the genetic driver for Huntingtons, researchers delved into the roles of the healthy and mutant HTT proteinsbiology that Paul Bolno, president and CEO of Wave Life Sciences, said has been interesting. We really realized that Huntingtons disease, in a lot of ways, is both a toxic gain of function and a toxic loss of function.
One challenge, Hayden told BioSpace, is that gene-silencing therapies, such as Roches tominersen, also knocked down the wildtype HTT (wtHTT) protein, which may be neuroprotective.
The pan-silencing hypothesis holds that there is a therapeutic window in which it is possible to reduce mutant HTT (mHTT) protein and concomitantly not reduce the wildtype HTT protein and keep that balance, explained Anne-Marie Li-Kwai-Cheung, Waves chief development officer, who previously led the tominersen efforts at Roche.
In a pan-silencing approach, you are succeeding, hopefully, in taking down the toxic protein, she told BioSpace. But the other half of the disease, which is a toxic loss of function, is that the wildtype [HTT] that you inevitably take out at the same time is actually really essential.
The question, Hayden posed, is would it not be better to have an allele-specific knockdown? This is the approach being taken by Wave. The companys next-generation antisense oligonucleotide (ASO) WVE-003 is designed to preferentially lower mHTT protein levels by targeting a single nucleotide polymorphism that appears on the mHTT transcript.
It is possible theres a therapeutic window, but if you can approach the problem more elegantly by being selective, that is by far the better approach in my opinion, Li-Kwai-Cheung said.
Delivery can also be a challenge, Hayden said. Intrathecal treatments, which are administered into the spinal canal, can also fail because you may not get target engagement or sufficient target engagement because you have to get from the CSF all the way deep into the center of the brain, Hayden said.
This was the case with Waves first-generation ASOs, according to the companys then chief medical officer, Michael Panzara.
Bolno believes Wave has solved this issue with WVE-003 in the form of a chemical modification to its platform. The PN chemistry weve been using . . . has really transformed what weve seen not just in terms of exposure [and] target engagement but durability, he said.
In September 2022, Wave presented data from the Phase Ib/IIa SELECT-HD trial showing a mean decrease in mHTT from baseline of 22% at 85 days. The mean reduction relative to placebo was 35% at 85 days after a single 30 mg or 60 mg. The company expects to share data from the 30 mg multi-dose cohort this quarter.
Prilenia is taking still another approach with pridopidine, a pill containing what the company describes as a highly selective and potent agonist of the sigma-1 receptor (S1R) protein, which is highly expressed in the brain and spinal cord and regulates several key processes that are commonly impaired in various neurodegenerative diseases.
Last month at the 75th American Academy of Neurology (AAN) Annual Meeting, Prilenia shared that pridopidine missed the primary endpoint, change from baseline compared to placebo at 65 weeks as measured by the Unified Huntington Disease Rating Scale-Total Functional Capacity score, in the Phase III PROOF-HD study. The drug also failed the key secondary endpoint, measured by the Composite Unified Huntingtons Disease Rating Scale.
Still, Hayden is optimistic as effects on both of these measures were reduced by the use of concomitant medications, according to the companys press release. A prespecified analysis that excluded participants taking neuroleptics and chorea medications showed clinically meaningful and nominally significant benefits with pridopidine.
When we looked then at those off of anti-dopaminergics [which includes neuroleptics], then we got a very different picture, Hayden said. In terms of total functional capacity, these patients remained stable for at least a year, and in terms of motor function and cognition, we saw improvement, he said. That was exciting because no [Huntingtons] drug had ever shown improvement in any of these functions.
Hayden additionally noted that the pridopidine is completely safe. There were no serious adverse events, and its . . . easy to take. When you look at risk-benefit, there is no risk and essentially patientsnot everybody, but many patientsderive benefit.
On the strength of these data, European regulators have encouraged Prilenia to submit a Marketing Authorization Application for approval, Hayden said, which the company plans to do by the end of July.
Its taken a long time, Hayden said, but the good news now is that Huntingtons disease has attracted the attention of pharma and biotech, big and small . . . and its recognized, sadly, that this is a disease that has been described as the worst disease known.
Li-Kwai-Cheung predicted there would be a disease-modifying therapy for Huntingtons within 5 to 10 years. Sometimes people get this feeling of like, its just futile and were not going to get there. But I dont think thats true, she said. I think all of these experiments have served a purpose to move the field forwards, and we really are on like the cusp as a field of getting a therapeutic to the market in [Huntingtons disease].
And once that happens, Weve seen in lots of different neurological spaces that that first approval really acts as an incredible catalyst and more drugs come after that as well.
Heather McKenzie is a senior editor atBioSpace. You can reach her atheather.mckenzie@biospace.com. Also follow her onLinkedIn.
Read more:
30 Years After Genetic Discovery, Huntingtons Patients Still Waiting - BioSpace
- Genetics colloquium: Chris Hittinger on the genomic making of metabolic niche breadth Sep. 11 - University of WisconsinMadison - September 15th, 2024 [September 15th, 2024]
- NIH Recognizes Yales Expertise in the Genetics of Rare Diseases - Yale School of Medicine - September 15th, 2024 [September 15th, 2024]
- SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing - PR Newswire - September 15th, 2024 [September 15th, 2024]
- Medicines race dilemma: What science says about genetics and health [PODCAST] - Kevin MD - September 15th, 2024 [September 15th, 2024]
- Researchers want to unlock genetics of the worlds tiniest animals - Popular Science - September 15th, 2024 [September 15th, 2024]
- Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout - Medical Device Network - September 15th, 2024 [September 15th, 2024]
- From farm to future: Technology in genetics - National Hog Farmer - September 2nd, 2024 [September 2nd, 2024]
- Editorial: Plant biotechnology and genetics for sustainable agriculture and global food security - Frontiers - September 2nd, 2024 [September 2nd, 2024]
- NSF Grant Brings Genetics Opportunities to Students in Alabama - Government Technology - September 2nd, 2024 [September 2nd, 2024]
- SBUs Ben Luft brings Lyme expertise to seminal paper on bacterial genetics and evolution - TBR News Media - September 2nd, 2024 [September 2nd, 2024]
- SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference - PR Newswire - September 2nd, 2024 [September 2nd, 2024]
- Singapores National Precision Medicine (NPM) Programme Engages Oxford Nanopore to Advance Understanding of the Genetics of Singapores Multi-Ethnic... - August 5th, 2024 [August 5th, 2024]
- Fulgent Genetics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - August 5th, 2024 [August 5th, 2024]
- Stopped clinical trials give evidence for the value of genetics - Nature.com - August 5th, 2024 [August 5th, 2024]
- What is DSD? Sex genetics and Olympic boxing controversy - Washington Examiner - August 5th, 2024 [August 5th, 2024]
- Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue - The Motley Fool - August 5th, 2024 [August 5th, 2024]
- Viewpoint: Challenging yet another scientifically silly article claiming Black domination of sprinting and long distance running has nothing to do... - August 5th, 2024 [August 5th, 2024]
- Texas Company Trying To Resurrect Woolly Mammoths To Improve Genetics Of Bison - Cowboy State Daily - August 5th, 2024 [August 5th, 2024]
- Genetics confirms Berbers reached North Africa over 20,000 years ago; Arabs came in 7th Century CE - Down To Earth Magazine - August 5th, 2024 [August 5th, 2024]
- Unlocking plant genetics with telomere-to-telomere genome assemblies - Nature.com - July 26th, 2024 [July 26th, 2024]
- Carlo Ancelotti claims Jude Bellingham's 'genetics' are main reason behind Real Madrid & England superstar's meteoric rise to the top - Goal.com - July 26th, 2024 [July 26th, 2024]
- Genetics-based modeling estimates Idaho's wolf population was 1,150 in summer 2023 - Idaho Fish and Game - July 26th, 2024 [July 26th, 2024]
- Lung Cancer Research Foundation Joins Lung Cancer Advocacy Organizations and 23andMe to Launch Lung Cancer Genetics Study to Advance Research - PR... - July 26th, 2024 [July 26th, 2024]
- Fulgent Genetics (FLGT) Scheduled to Post Earnings on Friday - Defense World - July 26th, 2024 [July 26th, 2024]
- SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix - Financial Times - July 26th, 2024 [July 26th, 2024]
- LG Household & Health Care publishes research into the genetics of skin tone - GlobalCosmeticsNews - July 26th, 2024 [July 26th, 2024]
- Estonians gave their DNA to science now they're learning their genetic secrets - Nature.com - June 27th, 2024 [June 27th, 2024]
- Genetic clues to depression revealed in large study - PsyPost - June 27th, 2024 [June 27th, 2024]
- Move Over, Genghis Khan. Many Other Men Left Huge Genetic Legacies - Smithsonian Magazine - June 27th, 2024 [June 27th, 2024]
- 3X4 Genetics Selected as Partner for Preeminent Cancer Research and Treatment Nonprofit, The Metabolic Terrain ... - BioSpace - June 27th, 2024 [June 27th, 2024]
- NIFA Invests $6M in Animal Breeding, Genetics and Genomics | NIFA - National Institute of Food and Agriculture - June 27th, 2024 [June 27th, 2024]
- Arbel Harpak: Pursuing the Next Frontier in Genetics | Dell Medical School - Dell Medical School - June 27th, 2024 [June 27th, 2024]
- Coffee habits are partly linked to genetics, UC San Diego researchers say - NBC San Diego - June 27th, 2024 [June 27th, 2024]
- Advanced genetic tools help researchers ID new neurodevelopmental syndrome - Yale News - June 27th, 2024 [June 27th, 2024]
- Nutritious diet may protect against type 2 diabetes, regardless of genetics - News-Medical.Net - June 27th, 2024 [June 27th, 2024]
- Genome-wide association study identifies host genetic variants influencing oral microbiota diversity and metabolic ... - Nature.com - June 27th, 2024 [June 27th, 2024]
- Unlock the Secrets of Your DNA with Advanced Genetic Testing - North Forty News - June 27th, 2024 [June 27th, 2024]
- Modern and precise: Using gene editing to change the blueprint of an organism - Beef Magazine - June 27th, 2024 [June 27th, 2024]
- The 'gene deserts' unravelling the mysteries of disease - BBC.com - June 27th, 2024 [June 27th, 2024]
- UGA plant geneticists are tackling the climate crisis - Longview News-Journal - June 27th, 2024 [June 27th, 2024]
- Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA - TCTMD - June 27th, 2024 [June 27th, 2024]
- Bringing Gene Therapy to the Brain - The Scientist - June 27th, 2024 [June 27th, 2024]
- The importance of the paradise fish in evolutionary and behavioral genetics research - Phys.org - June 9th, 2024 [June 9th, 2024]
- What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing? - Yahoo Finance - June 9th, 2024 [June 9th, 2024]
- UW initiative aims to bring together social sciences and genetics - Wisbusiness.com - June 9th, 2024 [June 9th, 2024]
- Women have a higher genetic risk for PTSD, according to study by VCU and Swedish researchers - VCU News - June 9th, 2024 [June 9th, 2024]
- Genetics study points to potential treatments for restless leg syndrome - University of Cambridge news - June 9th, 2024 [June 9th, 2024]
- deCODE genetics: The rate, nature and transmission of mitochondrial DNA mutations in humans - PR Newswire - June 9th, 2024 [June 9th, 2024]
- Genetic association mapping leveraging Gaussian processes | Journal of Human Genetics - Nature.com - June 9th, 2024 [June 9th, 2024]
- Minimally destructive hDNA extraction method for retrospective genetics of pinned historical Lepidoptera specimens ... - Nature.com - June 9th, 2024 [June 9th, 2024]
- Restless legs syndrome tied to 140 'hotspots' in the genome - Livescience.com - June 9th, 2024 [June 9th, 2024]
- Paired tumor-germline testing can enhance patient carewith guidance from genetics specialists - The Cancer Letter - June 9th, 2024 [June 9th, 2024]
- Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets - Nature.com - June 9th, 2024 [June 9th, 2024]
- Genetic Risk Score Revolutionizes TNBC Prediction in Black Women - Targeted Oncology - June 9th, 2024 [June 9th, 2024]
- Gene variants and breast cancer risk in Black women - National Institutes of Health (NIH) (.gov) - June 9th, 2024 [June 9th, 2024]
- GSA-MiXeR: A powerful tool to improve our understanding of heritable traits and diseases - News-Medical.Net - June 9th, 2024 [June 9th, 2024]
- Understanding the effect genetics have on Alzheimer's - Buffalo News - June 9th, 2024 [June 9th, 2024]
- 'Fossil viruses' embedded in the human genome linked to psychiatric disorders - Livescience.com - June 9th, 2024 [June 9th, 2024]
- Louisiana Sports Hall of Fame Profile: Ardoin's genetics provided gift for writing, and his versatility made him legendary - crescentcitysports.com - June 9th, 2024 [June 9th, 2024]
- Genes Link Sleep Patterns to Autism and Bipolar Disorder - Neuroscience News - June 9th, 2024 [June 9th, 2024]
- Tilapia genetics: a comparative trial between two strains in Brazil - The Fish Site - June 1st, 2024 [June 1st, 2024]
- New genetic cause of intellectual disability potentially uncovered in 'junk DNA' - Livescience.com - June 1st, 2024 [June 1st, 2024]
- Scientists identify gene that could lead to resilient 'pixie' corn - College of Agriculture and Life Sciences - June 1st, 2024 [June 1st, 2024]
- Veritas Genetics at the forefront of genomic screening with new studies presented at the European Society of Human ... - PR Newswire - June 1st, 2024 [June 1st, 2024]
- Alzheimer's study suggests genetic cause of specific form of disease Harvard Gazette - Harvard Gazette - June 1st, 2024 [June 1st, 2024]
- Researchers Discover Genetic Underpinnings of Inherited Condition Often Misdiagnosed as Hypothyroidism - InventUM - University of Miami - June 1st, 2024 [June 1st, 2024]
- Too much or too little: The impact of protein dosage on development - EurekAlert - June 1st, 2024 [June 1st, 2024]
- Hussman Institute Celebrates National DNA Day with Frost Science Museum - InventUM - University of Miami - June 1st, 2024 [June 1st, 2024]
- International treaty agreed on handling genetics in patents - Research Professional News - June 1st, 2024 [June 1st, 2024]
- Nebraska team identifies new genetic defect impacting cattle morbidity and meat quality - Beef Magazine - June 1st, 2024 [June 1st, 2024]
- Exploring the wonders of molecular biology - Drug Target Review - June 1st, 2024 [June 1st, 2024]
- Arn Anderson Bron Breakker Has Got His Dads Genetics, Will Be A Big Star - eWrestlingNews - June 1st, 2024 [June 1st, 2024]
- Genetic research: possibilities and risks Exaudi - Exaudi - June 1st, 2024 [June 1st, 2024]
- Study shows effect of 'interaction' on epigenetic marking in... - Parkinson's News Today - June 1st, 2024 [June 1st, 2024]
- The same genetic mutations behind gorillas' small penises may hinder fertility in men - Livescience.com - May 24th, 2024 [May 24th, 2024]
- Genetics reveals surprising origin of the German cockroach - Cosmos - May 24th, 2024 [May 24th, 2024]
- Genetics Reveals The Mysterious Origins Of The Cockroach - Forbes - May 24th, 2024 [May 24th, 2024]
- Optimizing genetics to advance controlled environment agriculture - AgriLife Today - AgriLife Today - May 24th, 2024 [May 24th, 2024]
- Genetics help combat illegal movement of feral swine - The Wildlife Society - May 24th, 2024 [May 24th, 2024]
- Tracking the cellular and genetic roots of neuropsychiatric disease - Yale News - May 24th, 2024 [May 24th, 2024]